Download PDF
Nuklearmedizin 1989; 28(01): 21-25
DOI: 10.1055/s-0038-1629465
Original Articles
Schattauer GmbH

Pertechnetate Uptake in the Prediction of Early Outcome after Radioiodine Therapy

Pertechnetat-Uptake in der Vorhersage des frühen Ergebnisses nach Radiojod-Therapie
T. M. D. Gimlette
1   From the Department of Nuclear Medicine, Royal Liverpool Hospital, Liverpool, England
› Author Affiliations
Further Information

Publication History

Received: 24 October 1988

Publication Date:
05 February 2018 (online)

Also available at
    Permissions and Reprints

99mTc-pertechnetate uptake was estimated 8-13 weeks after radioiodine therapy for hyperthyroidism in 132 patients in order to evaluate the usefulness of the uptake test in predicting both persisting hyperthyroidism and the early onset of hypothyroidism during the first year after therapy. The estimation was simple, the result immediately available, and its sensitivities, positive predictive value and its overall accuracy (83%) compared favourably with that of in-vitro tests, FT4I (75%) and FT3I (80%), carried out on the same occasions during the early follow-up period. Pertechnetate uptake can be a useful guide to management by promptly identifying patients likely to need further radioiodine therapy and those with transient or permanent hypothyroidism. The study confirmed some previous findings that hypothyroidism was more frequent in patients with thyroid antibodies and less frequent in patients with nodular thyroids, and it also indicated that hypothyroidism was more frequent in those treated with carbimazole before and after radioiodine, and that hyperthyroidism was more likely to persist in those treated with carbimazole before or after radioiodine.

Zusammenfassung

Bei 132 Patienten wurde die 99mTc- Pertechnetat-Speicherung 8-13 Wochen nach einer Radiojodbehandlung einer Hyperthyreose bestimmt, um die Brauchbarkeit des Speichertests zur Prognose sowohl einer persistierenden Hyperthyreose als auch des frühen Auftretens einer Hypothyreose während des ersten Jahres nach der Therapie zu prüfen. Die Methode war einfach, das Ergebnis sofort verfügbar und die Empfindlichkeit, der positive Voraussagewert und die Gesamtgenauigkeit (83%) waren jener von In-vitro-Tests wie FT4I (75%) und FT3I (80%), die bei der selben Gelegenheit durchgeführt wurden, überlegen. Die Pertechnetat-Speicherung kann ein nützliches Mittel sein, um rasch Patienten zu erkennen, die eine weitere Radiojodbehandlung brauchen, und solche mit vorübergehender oder dauernder Hypothyreose. Die Studie bestätigte gewisse frühere Beobachtungen, wonach eine Hypothyreose häufiger bei Patienten mit Schilddrüsenantikörpern und weniger häufig bei Patienten mit knotigen Strumen auftritt. Sie zeigte ferner, daß eine Hypothyreose bei jenen Patienten häufiger zu beobachten ist, die vor und nach Radiojod mit Karbimazol behandelt wurden, und daß eine Hyperthyreose bei Patienten, die vor oder nach Radiojod mit Karbimazol behandelt wurden, eher anhält.

 

  • REFERENCES

  • 1 Alexander W D, McLarty D G, Robertson J. et al. Prediction of the long-term results of antithyroid drug therapy for thyrotoxicosis. J Clin Endocrinol Metab 1971; 30: 540-3.
    Google Scholar
  • 2 Braverman L E, Woeber K A, Ingbar S H. Induction of myxedema by iodide in patients euthyroid after treatment of toxic goitre. N Engl J Med 1969; 281: 816-21.
    CrossrefPubMedGoogle Scholar
  • 3 Connell J MC, Hilditch T E, Robertson J, Coghill G, Alexander W D. Radioprotective action of carbimazole in radioiodine therapy for thyrotoxicosis - influence of the drug on iodine kinetics. Eur J Nucl Med 1987; 13: 358-61.
    PubMedGoogle Scholar
  • 4 Crooks J, Buchanan W W, Wayne E J, McDonald E. Effect of pre-treatment with carbimazole on early outcome following radioiodinc (13II) therapy. Br Med J 1960; i: 151-4.
    Google Scholar
  • 5 Dorfman S G, Young R L, Carfetta R F. Transient hypothyroidism. Arch Int Med 1977; 137: 256-7.
    CrossrefGoogle Scholar
  • 6 Gimlette T MD, Kocak R, Herbert R G, Squire C R. The effect of carbimazole following radioiodine therapy on radiation dose to the thyroid. Nucl-Med 1981; 20: 72-5.
    Google Scholar
  • 7 Gimlette T MD, Critchley M, Squire C R. Factors predicting hypothyroidism in longterm follow-up after 1311 therapy. Nucl-Med 1988; 27: 135-9.
    Google Scholar
  • 8 Goolden A WG, Fraser T R. The effect of pre-treatment with carbimazole in patients with thyrotoxicosis subsequently treated with radioactive iodine. Br Med J 1969; ii: 443-4.
    Google Scholar
  • 9 Hurley P J, Maiscy M N, Natavajan T K, Wagner H N. A computerized system for rapid evaluation of thyroid function. J Clin Endocrinol Metab 1972; 34: 352-60.
    Google Scholar
  • 10 Segal R C, Silver S, Yohalem S M, Feitclberg S. Myxedema following radioactive iodine therapy of hyperthyroidism. Am J Med 1961; 31: 354-7.
    CrossrefPubMedGoogle Scholar
  • 11 Squire C R, Gimlette T MD. Assessment of an enhanced chemiluminescent im- munometric assay for TSH on 1127 patients. Ann Clin Biochem 1987; 24: 419-25.
    CrossrefPubMedGoogle Scholar
  • 12 Toft A D, Hunter W M, Barnes E W, Seth J, Irvine W J. Raised plasma thyroid stimulating hormone levels in thyrotoxic patients treated- with iodine-131. Lancet 1973; ii: 644-5.
    PubMedGoogle Scholar
  • 13 Wilson R, McKillop J H, Pearson D WM, Cuthbert G F, Thomson J A. Relapse of Graves’ disease after medical therapy; predictive value of thyroidal technetium-99m uptake and serum thyroid stimulating hormone receptor antibody levels. J Nucl Med 1985; 26: 1024-7.
    PubMedGoogle Scholar
  • 14 Wilson R, McKillop J H, Black E, Jenkins C, Thomson J A. Early prediction of hypothyroidism following l3lI treatment for Graves’ disease. Eur J Nucl Med 1988; 14: 180-3.
    PubMedGoogle Scholar
  • 15 Wise P H, Ahmed A, Burnett R B. et al. Intentional radioiodine ablation in Graves’ disease. Lancet 1975; ii: 1231-2.
    PubMedGoogle Scholar